NCNA vs NGEN

NuCana plc vs NervGen Pharma Corp. — Valuation Comparison 2026

NCNA

Biotechnology
NuCana plc
Quality
1.7
out of 10
Value Trap
Price
$2.27
Last close
Models
6/13
Active
VS

NGEN

Biotechnology
NervGen Pharma Corp.
Quality
3.1
out of 10
Value Trap
Price
$2.08
Last close
Models
6/13
Active

Model-by-Model Comparison

ModelType NCNA Fair ValueNCNA Upside NGEN Fair ValueNGEN Upside
Bayesian DCF Intrinsic $0.60 -73.5% $0.64 -69.5%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $3.98 +85.3% $0.09 -95.6%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for NCNA vs NGEN — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

NCNA vs NGEN — Which Stock Is More Undervalued?

NGEN scores higher with a 3.1/10 quality rating vs NCNA's 1.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing NuCana plc (NCNA) and NervGen Pharma Corp. (NGEN) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

NCNA currently trades at $2.27 with a QOC of 1.7/10, while NGEN trades at $2.08 with a QOC of 3.1/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).